Kelonia Therapeutics
Kelonia Therapeutics is pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS®). The company's innovative technology enables precise, efficient, and tissue-specific gene delivery directly into patients, aiming to make genetic medicines accessible to every patient in need. Initially focused on developing transformational in vivo CAR T therapies for hematologic cancers, Kelonia is building a pipeline for a broad range of diseases, with the goal of expanding the impact and reach of genetic medicines.
Industries
Nr. of Employees
small (1-50)
Patents
Products
In vivo gene placement platform (targeted gene delivery)
A targeted in vivo gene delivery platform that uses engineered lentiviral vector-like particles with adjustable targeting ligands and optimized envelope/fusogen modifications to deliver genetic cargo to specific cell types after systemic or direct infusion.
In vivo gene placement platform (targeted gene delivery)
A targeted in vivo gene delivery platform that uses engineered lentiviral vector-like particles with adjustable targeting ligands and optimized envelope/fusogen modifications to deliver genetic cargo to specific cell types after systemic or direct infusion.
Services
Collaborative research and licensing arrangements to combine in vivo delivery capabilities with partner therapeutic platforms to develop immuno-oncology programs.
Partner-driven process and analytical development and commercial-scale manufacturing support for lentiviral vector-like particles through contract manufacturing collaborations.
Collaborative research and licensing arrangements to combine in vivo delivery capabilities with partner therapeutic platforms to develop immuno-oncology programs.
Partner-driven process and analytical development and commercial-scale manufacturing support for lentiviral vector-like particles through contract manufacturing collaborations.
Expertise Areas
- In vivo gene delivery
- CAR T therapy development
- Preclinical development and animal models
- Lentiviral vector process development and manufacturing
Key Technologies
- Lentiviral vector-based gene delivery
- Targeting ligand / tropism engineering
- Envelope and fusogen engineering
- In vivo CAR T generation